Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 Apr;31(4):413-7.
doi: 10.1111/j.1365-2125.1991.tb05555.x.

The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers

Affiliations
Clinical Trial

The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers

D R Robertson et al. Br J Clin Pharmacol. 1991 Apr.

Abstract

1. The pharmacokinetics of levodopa and paracetamol after single oral doses have been investigated in eight healthy young volunteers in the fasted state and following isocaloric meals containing either 10.5 g or 30.5 g of protein. 2. The initial peak and maximum plasma drug concentrations and the times at which these occurred were not affected by food. 3. The mean area under the plasma concentration-time curve (AUC) for paracetamol following an overnight fast did not differ significantly from that observed following the low and high protein meals. 4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min). However, there were no significant differences in the kinetics of levodopa between the fasting state and following the high protein meal. 5. There was no evidence that consumption of a meal containing 30.5 g of protein impaired either the rate or extent of absorption of levodopa. Therefore the reported beneficial effects of a low protein diet in the treatment of patients with Parkinson's disease probably result from reduced competition for levodopa transport across the blood-brain barrier.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Clin Invest. 1971 May;1(5):313-20 - PubMed
    1. Br J Clin Pharmacol. 1990 Jan;29(1):47-53 - PubMed
    1. Nature. 1973 Apr 13;242(5398):463-5 - PubMed
    1. N Engl J Med. 1975 Jan 23;292(4):181-4 - PubMed
    1. Lancet. 1976 Feb 7;1(7954):292-6 - PubMed

Publication types